The Impact of Immunosuppressive Drugs on Human Placental Explants

Imagem de Miniatura
Arquivos
art_GOMES_The_Impact_of_Immunosuppressive_Drugs_on_Human_Placental_2019.PDF (776.83 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SAGE PUBLICATIONS INC
Autores
GOMES, Sara Z.
ARAUJO, Franciele
BANDEIRA, Carla L.
OLIVEIRA, Leandro G.
BEVILACQUA, Estela
Citação
REPRODUCTIVE SCIENCES, v.26, n.9, p.1225-1234, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The use of immunosuppressive drugs guarantees the vitality of the graft and allows gestation in spite of intercurrences such as prematurity and intrauterine growth restriction. However, little is known about the direct effects of immunosuppressive drugs on placental cells. We investigated the effects of immunosuppressive drugs in the chorionic villous explants from human term placentas of healthy gestations. Human placental explants from term gestations (37-39 week gestational age, n = 12) were exposed to cyclosporine A (CSA, 0, 62.5, 125, 1250 ng/mL) or azathioprine (AZA, 0, 5, 10, 100 ng/mL) separately or, in combination for up to 48 hours. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays showed a significant decrease in the explant metabolic activity between AZA and the control group (24 hours, 100 ng/mL, 48 hours, all concentrations, P < .005). Cyclosporin A (CsA) reduced cell activity when associated with AZA (48 hours, P < .005). Fibrinoid deposits increased in AZA-treated explants alone (5 ng/mL, 48 hours; 10 ng/mL, 24-48 hours; P < .005) or when associated with CsA (10 AZA/125 CsA, P < .05), whereas in CsA treatment alone, there was an augment in syncytial knots (24-48 hours, P < .005). The sFLT1 gene (24 hours, P < .05) and protein (P < .005) expression increased in AZA and CsA-treatments separately or in combination (P < .05). Placental growth factor increased in AZA (24 hours, 10 ng/mL) and CsA (125 ng/mL; P < .05). In conclusion, our data indicate that AZA primarily acts on the villous metabolism, perturbing placental homeostasis. Since these drugs may alter the balance of angiogenic factors in its selection for clinical application, their impact on the behavior of placental villous should be considered.
Palavras-chave
placenta, explants, sFLT1, PlGF, cyclosporine, azathioprine
URI
https://observatorio.fm.usp.br/handle/OPI/34053
Referências
  1. Alston PK, 2001, OBSTET GYNECOL SURV, V56, P289, DOI 10.1097/00006254-200105000-00024
  2. Armenti Vincent T, 2008, Transplant Rev (Orlando), V22, P223, DOI 10.1016/j.trre.2008.05.001
  3. Bar-Oz B, 2001, TRANSPLANTATION, V71, P1051, DOI 10.1097/00007890-200104270-00006
  4. Benirschke K, 2006, PATHOLOGY HUMAN PLAC
  5. Bergan S, 1997, THER DRUG MONIT, V19, P502, DOI 10.1097/00007691-199710000-00003
  6. BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311
  7. Bertolin K., 2010, Animal Reproduction, V7, P146
  8. Bhattacharjee P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141986
  9. Brogan PA, 2000, ARCH DIS CHILD, V83, P259, DOI 10.1136/adc.83.3.259
  10. Bukowski R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182874
  11. Chaabane W, 2016, ONCOTARGET, V7, P75616, DOI 10.18632/oncotarget.12313
  12. Colla L, 2018, J NEPHROL, V31, P361, DOI 10.1007/s40620-018-0477-3
  13. de Boer NKH, 2006, AM J GASTROENTEROL, V101, P1390, DOI 10.1111/j.1572-0241.2006.00538.x
  14. de Mattos AM, 2000, AM J KIDNEY DIS, V35, P333, DOI 10.1016/S0272-6386(00)70348-9
  15. Du MR, 2008, BIOL REPROD, V78, P1102, DOI 10.1095/biolreprod.107.063503
  16. Du MR, 2007, HUM REPROD, V22, P2528, DOI 10.1093/humrep/dem222
  17. Eklund BI, 2007, BIOCHEM PHARMACOL, V73, P1829, DOI 10.1016/j.bcp.2007.02.002
  18. Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297
  19. FRANK HG, 1994, ACTA ANAT, V150, P55
  20. Ghanem ME, 2005, EUR J OBSTET GYN R B, V121, P178, DOI 10.1016/j.ejogrb.2004.11.035
  21. Hoffmann M, 2001, J AM CHEM SOC, V123, P6404, DOI 10.1021/ja010378c
  22. Janssen NM, 2000, ARCH INTERN MED, V160, P610, DOI 10.1001/archinte.160.5.610
  23. Josephson MA, 2007, ADV CHRONIC KIDNEY D, V14, P156, DOI 10.1053/j.ackd.2007.01.006
  24. Josephson MA, 2011, SEMIN NEPHROL, V31, P100, DOI 10.1016/j.semnephrol.2010.10.009
  25. Kaufmann P, 1996, ANN ANAT, V178, P485, DOI 10.1016/S0940-9602(96)80102-6
  26. Lee AU, 2001, J HEPATOL, V35, P756, DOI 10.1016/S0168-8278(01)00196-9
  27. Malhotra SS, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658-017-0046-0
  28. Maltzman JS, 2003, J CLIN INVEST, V111, P1122, DOI 10.1172/JCI200318384
  29. Matalon ST, 2005, HUM REPROD, V20, P1390, DOI 10.1093/humrep/deh721
  30. Mayhew TM, 2002, PLACENTA, V23, P742, DOI 10.1053/plac.2002.0865
  31. Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
  32. Narasimha A, 2011, INDIAN J PATHOL MICR, V54, P15, DOI 10.4103/0377-4929.77317
  33. Norgard B, 2007, AM J GASTROENTEROL, V102, P1406, DOI 10.1111/j.1572-0241.2007.01216.x
  34. Oliveira LG, 2007, CLIN TRANSPLANT, V21, P301, DOI 10.1111/j.1399-0012.2006.00627.x
  35. Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200
  36. Pacheco Neto M, 2008, J BRAS PATOL MED LAB, V44, P161
  37. Parolin Mônica Beatriz, 2009, Arq. Gastroenterol., V46, P154, DOI 10.1590/S0004-28032009000200015
  38. PLATZEK T, 1994, CHEM-BIOL INTERACT, V93, P59, DOI 10.1016/0009-2797(94)90086-8
  39. Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991
  40. Riss TL, 2004, ASSAY DRUG DEV TECHN, V2, P51, DOI 10.1089/154065804322966315
  41. Ruifrok AC, 2003, APPL IMMUNOHISTO M M, V11, P85, DOI 10.1097/00022744-200303000-00014
  42. Sava RI, 2018, CLIN CARDIOL, V41, P220, DOI 10.1002/clc.22892
  43. Shah DA, 2015, BIOCHEM PHARMACOL, V95, P211, DOI 10.1016/j.bcp.2015.04.012
  44. Shibuya M, 2013, J BIOCHEM, V153, P13, DOI 10.1093/jb/mvs136
  45. Svetitsky S, 2018, TRANSPL P, V50, P1461, DOI 10.1016/j.transproceed.2018.02.092
  46. Thellin O, 2003, TOXICOLOGY, V185, P179, DOI 10.1016/S0300-483X(02)00607-8
  47. Townsend R, 2016, INTEGR BLOOD PRESS C, V9, P79, DOI 10.2147/IBPC.S77344
  48. Vause S, 2005, ANAEST INTENS CARE M, V6, P77, DOI 10.1383/anes.6.3.77.62220
  49. Verlohren S, 2012, CLIN SCI, V122, P43, DOI 10.1042/CS20110097
  50. Wang L, 2006, ONCOGENE, V25, P1629, DOI 10.1038/sj.onc.1209372
  51. Wang SC, 2013, PLACENTA, V34, P374, DOI 10.1016/j.placenta.2013.01.009
  52. Ye L, 2016, PLACENTA, V48, P110, DOI 10.1016/j.placenta.2016.10.013
  53. Yu NH, 2017, J CELL BIOCHEM, V118, P2208, DOI 10.1002/jcb.25867
  54. Zand MS, 2005, SEMIN DIALYSIS, V18, P511, DOI 10.1111/j.1525-139X.2005.00098.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/57